Responses
Regular and young investigator award abstracts
Combination immunotherapies
440 Activity and safety of camrelizumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced non-small-cell lung cancer
Compose a Response to This Article
Other responses
No responses have been published for this article.